What are the manufacturers of Seleniso?

Selinexor (Selinexor) is a new type of anti-tumor drug mainly used to treat relapsed or refractory multiple myeloma and certain types of lymphoma. Its mechanism is to enhance the sensitivity of tumor cells to anti-cancer drugs by inhibiting nuclear export protein (exportin 1, XPO1).

In terms of production and sales, the main manufacturer of selinesol isKaryopharm Therapeutics Inc (Karyopharm Therapeutics Inc) . The company is a biopharmaceutical company focused on developing innovative treatments for cancer and other serious diseases. Karyopharm is responsible for the research and development, production and marketing of selinesol. In addition to Karyopharm, some other pharmaceutical companies may be involved in clinical trials, joint development or licensed production of selinesol, but its main production and commercialization rights still belong to Karyopharm. The production of such drugs usually involves strict supervision and quality control to ensure the safety and effectiveness of the drugs.

Seleniso is available by prescription only, and treatment should be initiated and supervised by a doctor experienced in treating cancer. Selinisol can be taken as a tablet orally once a week when used in combination with other medicines (bortezomib and dexamethasone) or twice a week when used only with dexamethasone. Dosage depends on the treatment combination used. Treatment can continue as long as the patient is benefiting from it.

Currently, demand for selinesol is gradually growing in the global market, especially among some patient groups who have not responded well to traditional treatments. There are also generic Seleniso drugs on the market overseas, such as Laos Lucius Pharmaceuticals, Laos Daxiong Pharmaceuticals, etc. The ingredients and efficacy of the drugs they produce are basically the same as those of the original drugs, but the price may be relatively lower.